JP2011521976A5 - - Google Patents

Info

Publication number

JP2011521976A5

JP2011521976A5 JP2011511892A JP2011511892A JP2011521976A5 JP 2011521976 A5 JP2011521976 A5 JP 2011521976A5 JP 2011511892 A JP2011511892 A JP 2011511892A JP 2011511892 A JP2011511892 A JP 2011511892A JP 2011521976 A5 JP2011521976 A5 JP 2011521976A5

Authority

JP

Japan

Prior art keywords

strain

gene

vaccine

pora

genetically modified

Prior art date

2009-06-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229960005486 vaccine Drugs 0.000 claims description 105
• 108090000623 proteins and genes Proteins 0.000 claims description 70
• 230000002779 inactivation Effects 0.000 claims description 49
• 230000014509 gene expression Effects 0.000 claims description 35
• 101710116435 Outer membrane protein Proteins 0.000 claims description 28
• 101100203230 Neisseria meningitidis serogroup B (strain MC58) siaA gene Proteins 0.000 claims description 23
• 241000588650 Neisseria meningitidis Species 0.000 claims description 22
• 101710186862 Factor H binding protein Proteins 0.000 claims description 21
• 101150093941 PORA gene Proteins 0.000 claims description 21
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 238000003780 insertion Methods 0.000 claims description 20
• 230000037431 insertion Effects 0.000 claims description 20
• 230000001965 increasing effect Effects 0.000 claims description 19
• 208000037941 meningococcal disease Diseases 0.000 claims description 18
• 238000000034 method Methods 0.000 claims description 16
• 238000012239 gene modification Methods 0.000 claims description 12
• 230000005017 genetic modification Effects 0.000 claims description 12
• 235000013617 genetically modified food Nutrition 0.000 claims description 12
• 101150093628 opaD gene Proteins 0.000 claims description 12
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
• 239000012528 membrane Substances 0.000 claims description 8
• 101150031431 opa gene Proteins 0.000 claims description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
• 239000008103 glucose Substances 0.000 claims description 6
• 230000003053 immunization Effects 0.000 claims description 6
• 238000002649 immunization Methods 0.000 claims description 6
• IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 6
• 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 6
• 239000002609 medium Substances 0.000 claims description 5
• 230000010473 stable expression Effects 0.000 claims description 5
• 201000009906 Meningitis Diseases 0.000 claims description 4
• 108010031133 Transferrin-Binding Protein A Proteins 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 4
• 230000000844 anti-bacterial effect Effects 0.000 claims description 4
• 239000001963 growth medium Substances 0.000 claims description 4
• 229910052742 iron Inorganic materials 0.000 claims description 4
• RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 239000002904 solvent Substances 0.000 claims description 4
• 239000004094 surface-active agent Substances 0.000 claims description 4
• STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 4
• 241001465754 Metazoa Species 0.000 claims description 3
• 239000000427 antigen Substances 0.000 claims description 3
• 102000036639 antigens Human genes 0.000 claims description 3
• 108091007433 antigens Proteins 0.000 claims description 3
• 238000005119 centrifugation Methods 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• -1 lacto-N-neotetraose tetrasaccharide Chemical class 0.000 claims description 3
• 230000004048 modification Effects 0.000 claims description 3
• 238000012986 modification Methods 0.000 claims description 3
• 206010059866 Drug resistance Diseases 0.000 claims description 2
• 108010052285 Membrane Proteins Proteins 0.000 claims description 2
• 102000018697 Membrane Proteins Human genes 0.000 claims description 2
• 108700026244 Open Reading Frames Proteins 0.000 claims description 2
• 108010031127 Transferrin-Binding Protein B Proteins 0.000 claims description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
• 230000002950 deficient Effects 0.000 claims description 2
• 238000000855 fermentation Methods 0.000 claims description 2
• 230000004151 fermentation Effects 0.000 claims description 2
• 229930182830 galactose Natural products 0.000 claims description 2
• 230000028993 immune response Effects 0.000 claims description 2
• 230000000415 inactivating effect Effects 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 2
• 239000002773 nucleotide Substances 0.000 claims description 2
• 125000003729 nucleotide group Chemical group 0.000 claims description 2
• 230000009450 sialylation Effects 0.000 claims description 2
• YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 2
• 150000004044 tetrasaccharides Chemical class 0.000 claims description 2
• 101150076489 B gene Proteins 0.000 claims 1
• 241000894006 Bacteria Species 0.000 claims 1
• 102100030386 Granzyme A Human genes 0.000 claims 1
• 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 1
• 108700026220 vif Genes Proteins 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 7
• 230000000890 antigenic effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 241000233866 Fungi Species 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1